Takeda Pharmaceutical
292 hedge funds and large institutions have $1.51B invested in Takeda Pharmaceutical in 2021 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 88 increasing their positions, 92 reducing their positions, and 38 closing their positions.
189% more call options, than puts
Call options by funds: $66.6M | Put options by funds: $23.1M
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
0.2% less ownership
Funds ownership: 6.02% → 5.81% (-0.2%)
4% less repeat investments, than reductions
Existing positions increased: 88 | Existing positions reduced: 92
4% less funds holding
Funds holding: 304 → 292 (-12)
6% less capital invested
Capital invested by funds: $1.6B → $1.51B (-$92.6M)
24% less first-time investments, than exits
New positions opened: 29 | Existing positions closed: 38
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
+$35.6M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$32.2M |
| 3 |
Goldman Sachs
New York
|
+$12M |
| 4 |
Barclays
London,
United Kingdom
|
+$7.28M |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
+$5.65M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$33.4M |
| 2 |
Northern Trust
Chicago,
Illinois
|
-$33.1M |
| 3 |
GCM
Glenview Capital Management
New York
|
-$17M |
| 4 |
GC
GMT Capital
Atlanta,
Georgia
|
-$9.46M |
| 5 |
LP
LMR Partners
London,
United Kingdom
|
-$8.69M |
TAK Hedge Fund Activity: Q3 2021 in Review
292 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Takeda Pharmaceutical (TAK) for Q3 2021, worth a combined $1.51B — down 5.8% from $1.6B a quarter earlier.
Sellers outnumbered buyers: 38 funds closed out of TAK and 29 opened new positions — a net loss of 9 holders — while 92 trimmed existing stakes and 88 added.
The largest buyer was Citigroup, adding an estimated $35.6M. The largest seller was ARK Investment Management, cutting an estimated $33.4M.
- 292 institutional investors held Takeda Pharmaceutical (TAK) as of Q3 2021, down from 304 in Q2 2021.
- Funds reported $1.51B of Takeda Pharmaceutical stock for Q3 2021, down 5.8% quarter-over-quarter.
- 29 funds opened new Takeda Pharmaceutical positions in Q3 2021 and 38 closed out, a net change of -9 holders.
- The largest Takeda Pharmaceutical buyer in Q3 2021 was Citigroup, an estimated $35.6M added.
- The largest Takeda Pharmaceutical seller in Q3 2021 was ARK Investment Management, an estimated $33.4M sold.
Based on aggregated 13F filings for Q3 2021.